Search Within

Human Oncology and Pathogenesis Program

Formats
  1. Journal Article (3002)
  2. Meeting Abstract (2555)
  3. Review (137)
  4. Editorial (106)
  5. Book Section (54)
  6. Research Letter (42)
  7. Guidelines (18)
  8. Correspondence (16)
  9. Miscellaneous (15)
  10. Conference Paper (13)
  11. Book Whole (3)
Groups
  1. GSK Faculty (5743)
  2. Department of Medicine (4298)
  3. Department of Pathology and Laboratory Medicine (3059)
  4. Tow Center for Developmental Oncology (TCDO) (2627)
  5. Solid Tumor Oncology Division (2617)
  6. Center for Molecular Imaging and Biotechnology (CMIB) (2570)

More Groups

People
  1. Marc Ladanyi (1330)
  2. Ross Levine (782)
  3. David Solit (780)
  4. Michael Berger (768)
  5. Nikolaus Schultz (488)
  6. Maria Arcila (426)

More People

Years
  1. 2025 (146)
  2. 2024 (380)
  3. 2023 (402)
  4. 2022 (451)
  5. 2021 (380)
  6. 2020 (457)

More Years

Publications
  1. Journal of Clinical Oncology (642)
  2. Blood (516)
  3. Cancer Research (412)
  4. Modern Pathology (299)
  5. Clinical Cancer Research (269)
  6. Laboratory Investigation (263)

More Publications

Publishers
  1. American Association for Cancer Research (874)
  2. Nature Publishing Group (761)
  3. American Society of Clinical Oncology (710)
  4. American Society of Hematology (563)
  5. Elsevier Inc. (420)
  6. Nature Research (312)

More Publishers

Results (5961)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Activation of MET signaling by the aberrant transcription factor ASPL-TFE3 and its therapeutic inhibition by RNA interference
    Meeting Abstract

    Tsuda, M.; Nagai, M.; Saito, T.; Lae, M.; Ladanyi, M.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • FLT PET as a non-invasive marker of response to MEK inhibition
    Meeting Abstract

    Solit, D. B.; Santos, E.; Pratilas, C. A.; Moroz, M.; Blasberg, R.; Sebolt-Leopold, J.; Larson, S.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Genetic and pharmacological inhibition of P13 kinase signaling in vivo sensitizes tumors to EGFR inhibitors and to taxol
    Meeting Abstract

    She, Q. B.; Ye, Q.; She, Y.; Solit, D. B.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • The Wnt/beta-catenin signaling pathway in synovial sarcoma: Mutational and functional analysis
    Meeting Abstract

    Saito, T.; Motoi, T.; Ladanyi, M.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • MAPK activation by B-RAF mutation or tyrosine kinase activation is associated with different patterns of feedback regulation that correlate with functional output of the pathway
    Meeting Abstract

    Pratilas, C. A.; Grbovic, O.; Sebolt-Leopold, J.; Rosen, N.; Solit, D. B.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • IGF-1 rescues rapamycin-induced cell growth inhibition
    Meeting Abstract

    O'reilly, K. E.; She, Q. B.; Solit, D. B.; Rosen, N.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • The Hedgehog Signaling Pathway in synovial sarcoma: Mutational and functional analysis
    Meeting Abstract

    Motoi, T.; Saito, T.; Ladanyi, M.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Phase I dose escalating trial of KOS-953 (heat shock protein 90 inhibitor) and trastuzumab (T)
    Meeting Abstract

    Modi, S.; Stopeck, A. T.; Gordon, M. S.; Solit, D.; Bagatell, R.; Ma, W.; Wheler, J.; Cropp, G. F.; Rosen, N.; Johnson, R. G. Jr; more...
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer
    Meeting Abstract

    Balak, M. N.; Riely, G. J.; Li, A. R.; Zakowski, M. F.; Ladanyi, M.; Miller, V. A.; Pao, W.
    Cancer Research (2006)

    Fulltext@MSK | Save
  • Human natural killer cells achieve tolerance by preferentially endowing functional competence to inhibitory killer Ig-like receptors specific for self-HLA class I
    Meeting Abstract

    Yu, J.; Pinto-Agnello, C.; Chewning, J.; Hsu, K. C.
    Blood (2006)

    Fulltext@MSK | Save